Patient with HIV achieves remission following stem cell transplant at City of Hope – City of Hope

Jana K. Dickter, M.D., City of Hope associate clinical professor in the Division of Infectious Diseases City of Hope announced July 27 that a 66-year-old man who was diagnosed with HIV in 1988 has been in remission from the virus for over 17 months after stopping antiretroviral therapy (ART) for the disease following a stem cell transplant from an unrelated donor for acute leukemia. Jana K.

Read more
St. John’s Researcher Studying Sharks for Clues to Cure Alzheimer’s, Parkinson’s Diseases – St John’s University News

July 28, 2022 Jai Dwivedi, Ph.D., Assistant Professor and Director of Laboratory Instruction in the Department of Biological Sciences at St. Johns University, has been fascinated by sharks since childhoodand that fascination has led him to research the species for clues to curing two vexing human conditions: Alzheimers and Parkinsons diseases. Its not as far-fetched as it sounds, Dr.

Read more
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency – BioSpace

WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc.(Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the first patient successfully received LV-RAG1 ex vivo lentiviral gene therapy to treat recombinase-activating gene-1 (RAG1) severe combined immunodeficiency (RAG1-SCID), in an ongoing Phase 1/2 multicenter clinical trial taking place in Europe. LV-RAG1 is exclusively licensed by Mustang for the development of MB-110, a first-in-class ex vivo lentiviral gene therapy for the treatment of RAG1-SCID. Patients with SCID have mutations in blood stem cell genes that are responsible for the development and function of infection-fighting immune cells.

Read more
Global Research Antibodies & Reagents Markets, 2022-2027 – Growth in Stem Cell and Neurobiology Research / Increasing Focus on Biomarker Discovery…

DUBLIN, July 25, 2022 /PRNewswire/ -- The 'Global Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western Blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End-user (Pharma, Biotech, CROs), and Region - Forecast to 2027'report has been added to ResearchAndMarkets.com's offering. Research and Markets Logo The global research antibodies and reagents market is projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7% The research antibodies and reagents market evolved owing to factors such as increasing proteomics and genomics research, growing demand for antibodies for research reproducibility, and increasing R&D expenditure in the life sciences industry

Read more